Disease marker combination enhances patient characterization in the Finnish sarcoidosis patients by Lahtela, E. et al.
lable at ScienceDirect
Respiratory Medicine 132 (2017) 92e94Contents lists avaiRespiratory Medicine
journal homepage: www.elsevier .com/locate/rmedShort communicationDisease marker combination enhances patient characterization in the
Finnish sarcoidosis patients
E. Lahtela a, *, A. Wolin a, A. Pietinalho b, M.-L. Lokki a, O. Selroos c
a Transplantation Laboratory, Medicum, University of Helsinki, Finland
b Raasepori Health Care Centre, Raasepori, Finland
c University of Helsinki, Helsinki, Finlanda r t i c l e i n f o
Article history:
Received 15 February 2017
Received in revised form
28 September 2017
Accepted 30 September 2017
Available online 3 October 2017
Keywords:
Angiotensin converting enzyme (ACE)
Human leukocyte antigen (HLA)
Prognosis
Sarcoidosis* Corresponding author. Transplantation Labora
(Haartmaninkatu 3), FIN-00014, University of Helsink
E-mail address: Laura.lahtela@helsinki.fi (E. Lahtel
https://doi.org/10.1016/j.rmed.2017.09.014
0954-6111/© 2017 Elsevier Ltd. All rights reserved.a b s t r a c t
Sarcoidosis is an inflammatory disease of unknown etiology and multiple clinical phenotypes. Clinical
manifestations range from asymptomatic disease to severe loss-of-function leading to the hypothesis
that sarcoidosis might not be just one disease, but consists of several distinct disease entities each with
potentially distinct genetic associations. We have previously demonstrated that in our series HLADRB1*
03:01 and haplotype HLA-DRB1*04:01-DPB1*04:01 are associated with good prognosis sarcoidosis. In
our recent work, we found a novel SNP (rs9905945) in the 50upstream region of the ACE gene to be
associated with favorable disease prognosis as well. The main objective of this study was to expand the
previous results and analyse combined influence of the found ACE SNP rs9905945 with the protective
HLA markers HLADRB1* 03:01 and HLA-DRB1*04:01-DPB1*04:01 in 188 Finnish sarcoidosis patients
(resolved disease, n ¼ 90; persistent disease, n ¼ 98). When combining the frequencies of the rs9905945
and of the HLA markers, the strongest association was found for a combination of either/or both HLA
markers and rs9905945 for good disease prognosis (37.1% in resolved vs. 11.3% in persistent, p < 0.001,
OR ¼ 4.61, (95%CI 2.15e9.86)). In conclusion, we discovered that a combination of the ACE SNP
rs9905945 and HLA markers enhance the accuracy for predicting disease course in Finnish sarcoidosis
patients further characterizing genetic differences between Finnish sarcoidosis patients with different
prognosis.
© 2017 Elsevier Ltd. All rights reserved.To the Editor
Sarcoidosis is an inflammatory disease of unknown etiology and
multiple clinical phenotypes. Clinical manifestations range from
asymptomatic disease to severe loss-of-function leading to the
hypothesis that sarcoidosis might not be just one disease, but
consists of several distinct disease entities each with potentially
distinct genetic associations [1]. This explains why no single gene
or immunological pathway defect has been found. Instead, a wide
range of genes have been identified, each contributing to relatively
minor effects and to a variety of clinical manifestations and dif-
ferences in prognosis. Nevertheless, there is strong evidence of
genetic influence in sarcoidosis, proposed by family studies and the
varying disease incidences in different ethnic groups [2,3].tory, Medicum, POBox 21
i, Finland.
a).One of the strongest genetic associations with sarcoidosis has
been found in the classical HLA genes in the major histocompati-
bility complex (MHC, 6p21.3). Associations have been found both in
class I [4] and class II [5e7] HLA genes, although the association
with class II seems to be more essential. Associations vary from
protective to predisposing alleles, or alleles influencing clinical
outcomes. Our group has reported that in Finnish sarcoidosis pa-
tients class II HLA-DRB1*03:01 and the haplotype HLA-DRB1*04:01-
DPB1*04:01 associate with a favorable disease outcome when
compared to Finnish control population or between sarcoidosis
prognosis groups [8,9]. The primary function of HLA-DR molecules
is to present fragments of antigenic peptides to specific CD4þ T
cells. Peptide-binding groove is an important part of the antigen
presentation. In sarcoidosis patients, vimentin peptide has been
identified to be presented in HLA molecules [10]. It is hypothesized
that vimentin could bind to HLA-DRB1*03 by using residues in
pockets 1, 4, 6 and 9 [11]. HLA-DRB1*03 and HLA-DRB1*04 differ in
peptide-binding amino acid sequences in these pockets (IMGT/
HLA). Thus, associationwithHLA-DRB1*03:01 andHLA-DRB1*04:01-
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Angiotensin-converting enzyme (ACE) gene in chromosome
17q23 has also been associated with sarcoidosis in many studies.
Most studied polymorphism in the ACE gene is the insertion, I and
deletion, D variation [10,12]. Besides the I/D variation, little atten-
tion has so far been paid to the role of other ACE variants in relation
to sarcoidosis [13]. Previously, our group wanted to extend the
knowledge of the ACE gene in sarcoidosis by genotyping 29 single
nucleotide polymorphisms (SNPs) spanning the gene from 5'up-
stream to 3'downstream [14]. These SNPs included tag SNP rs4343
for I/D polymorphism. We found a novel SNP (rs9905945) in the
5'upstream region of the ACE gene. Rs9905945 (C allele) associated
with favourable disease prognosis in Finnish sarcoidosis patients
further characterizing genetic differences between Finnish
sarcoidosis patients with different clinical outcomes. However,
when replicating in the Czech sarcoidosis patients, the SNP
rs9905945 did not show an association with prognosis of sarcoid-
osis, possibly reflecting the population-specific genotype
distribution.
The main objective of this study was to expand the previous
results and analyse the combined influence of the ACE SNP
rs9905945 with the protective HLA markers HLA-DRB1*03:01 and
HLA-DRB1*04:01-DPB1*04:01 in Finnish sarcoidosis patients. The
results might offer more accurate prognostic markers for evaluating
the disease course in Finnish patients.
Study subjects and patient characteristics have been previously
described in detail [9]. In summary, we examined a total of 188
Finnish patients recruited from 17 pulmonary units throughout the
country with verified pulmonary sarcoidosis followed-up for 5e15
years and clinically categorized into subgroups based on disease
prognosis. The patients were divided into those with a disease
resolved within 2 years (n ¼ 89) and to those with persisting ac-
tivity after 2 years (n ¼ 97). Disease activity after 2 years follow-up
was determined using the generally accepted WASOG (World As-
sociation of Sarcoidosis and Other Granulomatous diseases)
criteria. All the subjects gave their written informed consent to
participate in the genetic association study.
The C allele of the ACE SNP rs9905945, HLA-DRB1*03:01 and
HLA-DRB1*04:01-DPB1*04:01 were utilized for statistical analyses.
Chi-square and Fisher's exact test when appropriate were used to
assess significant differences in test marker frequencies
(rs9905945, HLA-DRB1*03:01 and HLA-DRB1*04:01-DPB1*04:01)
between the groups (persistent disease, resolved disease). The ef-
fect of test markers for sarcoidosis prognosis was analyzed with
logistic regression analysis (forward stepwise).
The C allele of the ACE SNP rs9905945 on the genotype level
showed independent association with good disease prognosisTable 1
Influence of significant good prognosis markers for Finnish sarcoidosis patients; HLA-D
region.









rs9905945 C phenotype 7
HLA-DRB1*03:01 þ rs9905945 C phenotype 2
HLA-DRB1*04:01-DPB1*04:01 þ rs9905945 C phenotype 1
HLA-DRB1*03:01/HLA-DRB1*04:01-DPB1*04:01 þ rs9905945 C phenotype 3
a Number of subjects: all, n ¼ 186; resolved, n ¼ 89; persistent, n ¼ 97.when tested together with HLA-DRB1*03:01 and the haplotype by
logistic regression (Table 1.). When combining the frequencies of
the rs9905945 C phenotypes and of the HLA-DRB1*03:01 and the
haplotype HLA-DRB1*04:01-DPB1*04:01, the strongest association
was found for a combination of either/or both HLA markers and
rs9905945 C allele for resolved disease prognosis (37.1% in resolved
vs. 11.3% in persistent, p < 0.001, OR ¼ 4.61, (95%CI 2.15e9.86)).
When stratifying for HLA markers in persistent and resolved study
groups, in the HLA-DRB1*03:01 stratified group, the rs9905945 C
phenotype did not show significantly different frequency between
resolved and persistent groups (80.6% in resolved vs. 56.3% in
persistent group, p ¼ 0.096, OR ¼ 3.24 (95%CI 0.86e12.3)). How-
ever, when comparing HLA-DRB1*04:01-DPB1*04:01 stratified
group, the frequency of rs9905945 C phenotype was more common
in resolved group (87.5% in resolved vs. 22.2% in persistent group,
p ¼ 0.002, OR ¼ 24.5 (95%CI 2.83e212.4)). Due to small sample
sizes, the stratified groups were combined. In the combined group
with either/or both HLA markers, the rs9905945 C phenotype
remained significantly more common in resolved group (80.5% in
resolved group vs. 44.0% in persistent group, p0.002, OR ¼ 5.25
(95%CI ¼ 1.74e15.8)).
In our previous studies, we have demonstrated that Finnish
resolved and persistent sarcoidosis patients have different combi-
nations of disease-related HLA markers (HLA-DRB1, -DPB1 and
BTNL2 polymorphism). We showed that combinations of markers
had higher distinction capability between severity of sarcoidosis
than these markers alone, indicating the need for analyzing not just
single association marker, but wider variety of predisposing or
protecting factors. In our series, HLA-DRB1*03:01 and the haplotype
HLA-DRB1*04:01-DPB1*04:01 positive patients are likely to develop
sarcoidosis that will resolve spontaneously within two years. Our
current study suggests that the novel association between
rs9905945 and the good disease prognosis is independent of the
HLA-DRB1*03:01 allele and the HLA-DRB1*04:01-DPB1*04:01
haplotype. However, the combination of the ACE SNP and HLA
markers seems to enhance specificity to detect different disease
outcomes compared to HLA markers alone.
To our knowledge, association between ACE and HLA molecules
in sarcoidosis has not been found before. The aetiology of the dis-
ease is unknown and it is thought to involve a complex interplay
between genes. Sarcoidosis is characterized by epithelioid granu-
lomas in affected organs [15]. Current understanding is that
antigen-presenting cells present peptides in a way that recognition
by CD4 T lymphocytes initiates an inflammatory response resulting
in granuloma formation [16] thus, explaining the HLA class II genes
in sarcoidosis susceptibility. On the other hand, epithelioid cells in
granulomas are the main source of ACE. High serum-ACE levels areRB1*03:01, haplotype HLA-DRB1*04:01-DPB1*04:01 and rs9905945 in the ACE gene
esolveda Persistenta Resolved vs. Persistent




4.8 16.5 0.004 2.71 (1.36e5.40)
6.9 6.2 0.022 3.07 (1.14e8.32)
4.9 22.7 0.001 2.78 (1.45e5.24)
9.8 66.0 0.035 2.03 (1.05e3.96)
8.1 9.3 0.001 3.82 (1.67e8.73)
5.7 2.1 0.001 8.87 (1.95e40.23)
7.1 11.3 <0.001 4.61 (2.15e9.86)
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granuloma mass and sarcoidosis activity [17] making the ACE gene
a potential susceptibility factor as well. Epithelioid cells of mucosal
surfaces have been shown to act as antigen-presenting cells, pre-
senting MHC class II molecules [18]. Epithelioid cell of granulomas
might therefore also present MHC II molecules, thus connecting
these two pathways.
In conclusion, we discovered that a combination of the ACE SNP
rs9905945 and previously reported HLA markers enhance the ac-
curacy for predicting disease course in Finnish sarcoidosis patients
further characterizing genetic differences between Finnish
sarcoidosis patients with different prognosis. However, probable
population specific distribution of the disease associated SNPsmust
be considered before its potential application to other populations.
Ethics statement
The study was performed with approval of Ethics Committee of
the Department of Internal Medicine, Hospital District of Helsinki
and Uusimaa, Finland.
Conflict of interest
The authors declare no known conflict of interest.
Funding
The study was supported by research grants from the Nummela
Foundation of Clinical Research.
Acknowledgements
The authors thank Leena Saraste for assisting with language
issues.
References
[1] P. Spagnolo, R.M. du Bois, Genetics of sarcoidosis, Clin. Dermatol 25 (3) (2007
May-Jun) 242e249.
[2] M.C. Iannuzzi, B.A. Rybicki, A.S. Teirstein, Sarcoidosis, N. Engl. J. Med. 357 (21)
(2007 Nov 22) 2153e2165.[3] J. Muller-Quernheim, M. Schurmann, S. Hofmann, K.I. Gaede, A. Fischer,
A. Prasse, et al., Genetics of sarcoidosis, Clin. Chest Med. 29 (3) (2008 Sep),
391,414, viii.
[4] J. Grunewald, A. Eklund, O. Olerup, Human leukocyte antigen class I alleles and
the disease course in sarcoidosis patients, Am. J. Respir. Crit. Care Med. 169 (6)
(2004 Mar 15) 696e702.
[5] H. Sato, F.A. Woodhead, T. Ahmad, J.C. Grutters, P. Spagnolo, J.M. van den
Bosch, et al., Sarcoidosis HLA class II genotyping distinguishes differences of
clinical phenotype across ethnic groups, Hum. Mol. Genet. 19 (20) (2010 Oct
15) 4100e4111.
[6] J. Grunewald, B. Brynedal, P. Darlington, M. Nisell, K. Cederlund, J. Hillert, et al.,
Different HLA-DRB1 allele distributions in distinct clinical subgroups of
sarcoidosis patients, Respir. Res. 11 (2010 Feb 26) 25.
[7] F. Mrazek, L.I. Holla, B. Hutyrova, V. Znojil, A. Vasku, V. Kolek, et al., Association
of tumour necrosis factor-alpha, lymphotoxin-alpha and HLA-DRB1 gene
polymorphisms with Lofgren's syndrome in Czech patients with sarcoidosis,
Tissue Antigens 65 (2) (2005 Feb) 163e171.
[8] A. Wennerstrom, A. Pietinalho, J. Lasota, K. Salli, I. Surakka, M. Seppanen, et al.,
Major histocompatibility complex class II and BTNL2 associations in sarcoid-
osis, Eur. Respir. J. 42 (2) (2013 Aug) 550e553.
[9] A. Wennerstrom, A. Pietinalho, H. Vauhkonen, L. Lahtela, A. Palikhe,
J. Hedman, et al., HLA-DRB1 allele frequencies and C4 copy number variation
in Finnish sarcoidosis patients and associations with disease prognosis, Hum.
Immunol. 73 (1) (2012 Jan) 93e100.
[10] J. Wahlstrom, J. Dengjel, B. Persson, H. Duyar, H.G. Rammensee, S. Stevanovic,
et al., Identification of HLA-DR-bound peptides presented by human bron-
choalveolar lavage cells in sarcoidosis, J. Clin. Invest. 117 (11) (2007 Nov)
3576e3582.
[11] J. Grunewald, Y. Kaiser, M. Ostadkarampour, N.V. Rivera, F. Vezzi, B. Lotstedt,
et al., T-cell receptor-HLA-DRB1 associations suggest specific antigens in
pulmonary sarcoidosis, Eur. Respir. J. 47 (3) (2016 Mar) 898e909.
[12] B. Rigat, C. Hubert, F. Alhenc-Gelas, F. Cambien, P. Corvol, F. Soubrier, An
insertion/deletion polymorphism in the angiotensin I-converting enzyme
gene accounting for half the variance of serum enzyme levels, J. Clin. Invest.
86 (4) (1990 Oct) 1343e1346.
[13] M. Schurmann, P. Reichel, B. Muller-Myhsok, T. Dieringer, K. Wurm,
M. Schlaak, et al., Angiotensin-converting enzyme (ACE) gene polymorphisms
and familial occurrence of sarcoidosis, J. Intern Med. 249 (1) (2001 Jan) 77e83.
[14] E. Lahtela, A. Wennerstr€om, A. Pietinalho, M. Petrek, V. Kolek, M.-L. Lokki,
O. Selroos, ACE gene variants and sarcoidosis in a Finnish population, Sar-
coidoisis, Vasc. diffuse lung Dis. 34 (2017) 104e114.
[15] L.S. Newman, C.S. Rose, L.A. Maier, Sarcoidosis, N. Engl. J. Med. 336 (17) (1997
Apr 24) 1224e1234.
[16] P. Spagnolo, L. Richeldi, R.M. du Bois, Environmental triggers and suscepti-
bility factors in idiopathic granulomatous diseases, Semin. Respir. Crit. Care
Med. 29 (6) (2008 Dec) 610e619.
[17] M. Luisetti, A. Beretta, L. Casali, Genetic aspects in sarcoidosis, Eur. Respir. J. 16
(4) (2000 Oct) 768e780.
[18] D.J. Mulder, A. Pooni, N. Mak, D.J. Hurlbut, S. Basta, C.J. Justinich, Antigen
presentation and MHC class II expression by human esophageal epithelial
cells, Am. J. Pathol. 178 (2) (2011 Feb) 744e753 doi: 10.1016, http://www.ebi.
ac.uk/ipd/imgt/hla.
